[go: up one dir, main page]

AP2922A - Carbra-nucleoside analogs for antiviral treatment - Google Patents

Carbra-nucleoside analogs for antiviral treatment

Info

Publication number
AP2922A
AP2922A AP2011005818A AP2011005818A AP2922A AP 2922 A AP2922 A AP 2922A AP 2011005818 A AP2011005818 A AP 2011005818A AP 2011005818 A AP2011005818 A AP 2011005818A AP 2922 A AP2922 A AP 2922A
Authority
AP
ARIPO
Prior art keywords
carbra
nucleoside analogs
antiviral treatment
antiviral
treatment
Prior art date
Application number
AP2011005818A
Other languages
English (en)
Other versions
AP2011005818A0 (en
Inventor
Thomas Butler
Aesop Cho
Choung U Kim
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42333309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2011005818A0 publication Critical patent/AP2011005818A0/xx
Application granted granted Critical
Publication of AP2922A publication Critical patent/AP2922A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2011005818A 2009-02-10 2010-02-09 Carbra-nucleoside analogs for antiviral treatment AP2922A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15124809P 2009-02-10 2009-02-10
PCT/US2010/023586 WO2010093608A1 (en) 2009-02-10 2010-02-09 Carba-nucleoside analogs for antiviral treatment

Publications (2)

Publication Number Publication Date
AP2011005818A0 AP2011005818A0 (en) 2011-08-31
AP2922A true AP2922A (en) 2014-05-31

Family

ID=42333309

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005818A AP2922A (en) 2009-02-10 2010-02-09 Carbra-nucleoside analogs for antiviral treatment

Country Status (26)

Country Link
US (1) US8012942B2 (xx)
EP (2) EP2396340B1 (xx)
JP (2) JP5746638B2 (xx)
KR (2) KR101724759B1 (xx)
CN (1) CN102348713B (xx)
AP (1) AP2922A (xx)
AU (3) AU2010213873B2 (xx)
BR (1) BRPI1013643A2 (xx)
CA (1) CA2751277C (xx)
CL (1) CL2011001906A1 (xx)
CO (1) CO6420354A2 (xx)
DK (1) DK2396340T3 (xx)
EA (1) EA025085B1 (xx)
ES (2) ES2628842T3 (xx)
HR (1) HRP20140219T1 (xx)
IL (1) IL214396A (xx)
MX (2) MX2011008409A (xx)
NZ (1) NZ594370A (xx)
PE (3) PE20161067A1 (xx)
PL (1) PL2396340T3 (xx)
PT (2) PT2396340E (xx)
SG (1) SG173186A1 (xx)
SI (1) SI2396340T1 (xx)
SM (1) SMT201400056B (xx)
UA (2) UA112140C2 (xx)
WO (1) WO2010093608A1 (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR112013001553B1 (pt) 2010-07-22 2021-01-12 Gilead Sciences, Inc. compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
JP2013538230A (ja) * 2010-09-20 2013-10-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013084165A1 (en) * 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
NZ628515A (en) 2012-02-10 2016-06-24 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
CN104470939B (zh) 2012-05-22 2017-04-26 埃迪尼克斯医药有限责任公司 用于肝脏疾病的d型氨基酸化合物
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
EA030189B8 (ru) 2012-10-08 2018-10-31 Иденикс Фармасьютикалз Ллс Аналоги 2'-хлоронуклеозидов для инфекции вгс
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CN105814068B (zh) * 2014-02-27 2017-08-04 四川海思科制药有限公司 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
DK3265102T3 (da) 2015-03-06 2025-10-13 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling
CN107709344B (zh) * 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
ES2918585T3 (es) 2015-09-16 2022-07-19 Gilead Sciences Inc Métodos para el tratamiento de infecciones por el virus Arenaviridae
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
HRP20250266T1 (hr) 2017-02-01 2025-04-25 Atea Pharmaceuticals, Inc. Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
JP2022518943A (ja) * 2019-02-01 2022-03-17 ヤンセン バイオファーマ インク． 抗ウイルスヌクレオシド及びその誘導体
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
PL4157272T3 (pl) 2020-05-29 2025-10-20 Gilead Sciences, Inc. Remdesiwir do leczenia zakażeń wirusowych
TWI819321B (zh) 2020-06-24 2023-10-21 美商基利科學股份有限公司 1'-氰基核苷類似物及其用途
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
EP4355319A4 (en) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. BENEFICIAL ANTI-HCV COMBINATION THERAPY
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
HUP0301112A3 (en) 2000-02-18 2005-04-28 Shire Biochem Inc Laval Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP2251015B1 (en) 2000-10-18 2013-02-20 Gilead Pharmasset LLC Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
RS50236B (sr) 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (de) * 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006050161A2 (en) * 2004-10-29 2006-05-11 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
JP2010513484A (ja) 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008085508A2 (en) 2007-01-05 2008-07-17 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
PT2114980E (pt) 2007-01-12 2012-09-25 Biocryst Pharm Inc Análogos de nucleósidos anti-virais
ES2393038T3 (es) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMANN, M. et al *
PATIL, SHIRISH A. et al *

Also Published As

Publication number Publication date
SG173186A1 (en) 2011-09-29
PE20160858A1 (es) 2016-09-03
ES2453078T3 (es) 2014-04-03
AU2010213873A1 (en) 2011-09-01
EA201190110A1 (ru) 2012-02-28
US20100203015A1 (en) 2010-08-12
PE20161067A1 (es) 2016-10-23
NZ594370A (en) 2014-01-31
SI2396340T1 (sl) 2014-04-30
IL214396A0 (en) 2011-09-27
SMT201400056B (it) 2014-07-07
PT2719701T (pt) 2017-06-29
AP2011005818A0 (en) 2011-08-31
UA110093C2 (uk) 2015-11-25
MX2011008409A (es) 2011-10-21
PL2396340T3 (pl) 2014-05-30
DK2396340T3 (en) 2014-03-10
IL214396A (en) 2014-07-31
HK1163108A1 (en) 2012-09-07
MX345562B (es) 2017-02-03
JP2012517444A (ja) 2012-08-02
BRPI1013643A2 (pt) 2016-04-19
PT2396340E (pt) 2014-03-26
JP5951690B2 (ja) 2016-07-13
ES2628842T3 (es) 2017-08-04
EP2396340A1 (en) 2011-12-21
WO2010093608A1 (en) 2010-08-19
JP5746638B2 (ja) 2015-07-08
AU2017202413B2 (en) 2018-09-13
EA025085B1 (ru) 2016-11-30
CN102348713B (zh) 2015-12-02
AU2017202413A1 (en) 2017-05-04
AU2015238785B2 (en) 2017-02-16
PE20120257A1 (es) 2012-03-29
KR101834707B1 (ko) 2018-03-05
JP2014185183A (ja) 2014-10-02
KR20170039759A (ko) 2017-04-11
EP2719701B1 (en) 2017-04-05
EP2719701A1 (en) 2014-04-16
CA2751277A1 (en) 2010-08-19
EP2396340B1 (en) 2013-12-18
AU2015238785A1 (en) 2015-10-29
CO6420354A2 (es) 2012-04-16
UA112140C2 (uk) 2016-07-25
KR20110116046A (ko) 2011-10-24
CA2751277C (en) 2018-10-30
CL2011001906A1 (es) 2012-03-30
KR101724759B1 (ko) 2017-04-07
CN102348713A (zh) 2012-02-08
AU2010213873B2 (en) 2015-07-09
US8012942B2 (en) 2011-09-06
HRP20140219T1 (hr) 2014-04-11

Similar Documents

Publication Publication Date Title
AP2922A (en) Carbra-nucleoside analogs for antiviral treatment
AP3076A (en) Carba-nucleoside analogs for antiviral treatment
HRP20171759T8 (hr) Antiviralni spojevi
IL248110A0 (en) Analogues of carba-nucleoside that are converted at the 2-position in fluorine for antiviral treatment
IL216026A0 (en) Heterocyckic antiviral compounds
GB0906209D0 (en) Antiviral compounds
GB0908677D0 (en) Antiviral compounds
GB0914473D0 (en) Antiviral compounds